Contribution of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in the management of anal carcinoma;Apport de la tomographie par émission de positons au 18F-fluorodéoxyglucose (TEP-FDG) dans la prise en charge du cancer du canal anal

Medecine Nucleaire

Volumn 33, Issue 7, 2009, Pages 415-424

  Renaud, S ^a   Guillemard, S ^a   Eberle Pouzeratte M C ^a   Lemanski, C ^a   Faurous, P ^a   Artus, J C ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

Anal canal; Epidermoid carcinoma; FDG PET; Therapeutic impact

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ANUS CARCINOMA; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

EID: 67650530004     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mednuc.2009.02.015     Document Type: Article

References (17)

1. Watrin B. Cancers épidermoïdes de l'anus. Rev Prat 51 (2001) 36-40
2. Maingon P, Truc G, Bosset JF, Gérard JP, Cuisenier J, Horiot JC. Cancer du canal anal. Encyclopédie Médico-Chirurgical. Gastroenterologie 2002 [9-084-D-10].
3. Ryan D., Compton C., and Mayer R. Carcinoma of the anal canal. N Engl J Med 16 (2000) 792-800
4. Scholefield J.H. Anal neoplasia epidemiological considerations. Acta Chir Austr 26 (1994) 352
5. Frisch M., Glimelius B., Van Der Brule A.J.C., Wohlfahrt J., Meijer C.J., Walboomers J.M., et al. Sexually tranmitted infection as a cause of anal cancer. N Engl J Med 337 (1997) 1350-1358
6. Northover J.M.A. Management of anal cancer. Past and present policy at St. Mark's. Acta Chir Austr 26 (1994) 361
7. Schlienger M, Touboul E, Balosso J, Pene J, Minne JF. Cancers épidermoïdes du canal anal. Cancers : évaluation, traitement et surveillance 1997.
8. Nigro N.D., Vaitkevicius K., and Considine B. Combined therapy for cancer of the anal canal. Dis Colon Rectum 27 (1974) 763-766
9. Trautmann T.G., and Zuger J.H. Positron emission tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 7 (2005) 309-313
10. Cotter S.E., Grigsby P.W., Siegel B.A., Dehdashti F., Malyapa R.S., Fleshman J.W., et al. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 65 (2006) 720-725
11. Nguyen B.T., Lim Joon D., Khoo V., Quong G., Chao M., Wada M., et al. Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol 87 (2008) 376-382
12. Schwarz J.K., Siegel B.A., Dehdashti F., Myerson R.J., Fleshman J.W., and Grigsby P.W. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 71 (2008) 180-186
13. Cohn D.E., Dehdashti F., Gibb R.K., Mutch D.G., Rader J.S., Siegel B.A., et al. Prospective evaluationof positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol 85 (2002) 179-184
14. Reinhardt M.J., Ehritt-Braun C., Vogelgesang D., Thling C., Hogerle S., Mix M., et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology 218 (2001) 776-782
15. Rose P.G., Adler L.P., Rodriguez M., Faulhaber P.F., Abdul-Karim F.W., and Miraldi F. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 17 (1999) 41-45
16. Fukunaga H., Sekimoto M., Ikeda M., Higuchi I., Yasui M., Seshimo I., et al. Fusion image of positron emission tomography and computed tomography for the diagnosis of local recurrence of rectal cancer. Ann Surg Oncol 12 (2005) 561-569
17. Sakurai H., Suzuki Y., Nonaka T., Ishikawa H., Shioya M., Kiyohara H., et al. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy - tumor volume and FDG uptake value. Gynecol Oncol 100 (2006) 601-607